Evolution and Clinical Impact of EGFR Mutations in Circulating Free DNA in the BELIEF Trial.

doi:10.1016/j.jtho.2019.11.023

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Evolution and Clinical Impact of EGFR Mutations in Circulating Free DNA in the BELIEF Trial.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Mar 2020

Molina-Vila Miguel-Angel, Stahel Rolf A, Dafni Urania, Jordana-Ariza Núria, Balada-Bel Ariadna, Garzón-Ibáñez Mónica, García-Peláez Beatriz, Mayo-de-Las-Casas Clara, Felip Enriqueta, Curioni Fontecedro Alessandra, Gautschi Oliver, Peters Solange, Massutí Bartomeu, Palmero Ramon, Ponce Aix Santiago, Carcereny Enric, Früh Martin, Pless Miklos, Popat Sanjay, Cuffe Sinead, Bidoli Paolo, Kammler Roswitha, Roschitzki-Voser Heidi, Tsourti Zoi, Karachaliou Niki, Rosell Rafael

Abstract excerpt

INTRODUCTION: Longitudinal evaluation of mutations in blood samples was a prespecified secondary objective in the BELIEF trial of erlotinib and bevacizumab in advanced EGFR-positive NSCLC. Here, we report the testing results and explore the correlation of EGFR status in blood with clinical outcomes. METHODS: Blood samples were prospectively collected from patients at baseline, at response evaluation, and at...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell-Free Nucleic Acids

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease-Free Survival

Share to DNA

Share to ErbB Receptors

Share to Lung Neoplasms

Share to Mutation

Share to Neoplasm Recurrence, Local

Share to Protein Kinase Inhibitors

Source

Open in PubMed

Identifiers

PMID: 31812754
DOI: 10.1016/j.jtho.2019.11.023

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 11 closest

Evolution and Clinical Impact of EGFR Mutations in Circulating Free DNA in the BELIEF Trial.PMID 31812754Read ↗

Association of EGFR L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial.Semantic proximity Read ↗

Routine EGFR molecular analysis in non-small-cell lung cancer patients is feasible: exons 18-21 sequencing results of 753 patients and subsequent clinical outcomes.Semantic proximity Read ↗

LungBEAM: A prospective multicenter study to monitor stage IV NSCLC patients with EGFR mutations using BEAMing technology.Semantic proximity Read ↗

Comparative analysis of EGFR mutations between circulating tumor DNA and tissue samples in non-small cell lung carcinoma patients using BEAMing PCR: results of a single institutional observational studySemantic proximity Read ↗

EGFR mutations detected in plasma are associated with patient outcomes in erlotinib plus docetaxel-treated non-small cell lung cancer.Semantic proximity Read ↗

Comparative analysis of EGFR mutations in circulating tumor DNA and primary tumor tissues from lung cancer patients using BEAMing PCR.Semantic proximity Read ↗

Longitudinal nonlinear mixed effects modeling of EGFR mutations in ctDNA as predictor of disease progression in treatment of EGFR-mutant non-small cell lung cancer.Semantic proximity Read ↗

Tracking the Evolution of Resistance to ALK Tyrosine Kinase Inhibitors Through Longitudinal Analysis of Circulating Tumor DNASemantic proximity Read ↗

Dynamic Evaluation of Circulating miRNA Profile in EGFR-Mutated NSCLC Patients Treated with EGFR-TKIs.Semantic proximity Read ↗

Changes in the concentration of EGFR-mutated plasma DNA in the first hours of targeted therapy allow the prediction of tumor response in patients with EGFR-driven lung cancer.Semantic proximity Read ↗

Monitoring of epidermal growth factor receptor tyrosine kinase inhibitor‐sensitizing and resistance mutations in the plasma DNA of patients with advanced non–small cell lung cancer during treatment with erlotinibSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.